ADMA Biologics (NASDAQ:ADMA) Trading Up 6.1% – Time to Buy?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s stock price was up 6.1% during trading on Wednesday . The stock traded as high as $19.91 and last traded at $19.85. Approximately 2,397,523 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 3,320,496 shares. The stock had previously closed at $18.71.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Trading Up 7.2 %

The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 71.57 and a beta of 0.60. The business’s 50 day moving average price is $16.67 and its two-hundred day moving average price is $17.98.

Institutional Investors Weigh In On ADMA Biologics

A number of institutional investors and hedge funds have recently modified their holdings of ADMA. Natixis Advisors LLC acquired a new stake in ADMA Biologics during the 3rd quarter valued at $345,000. Mutual of America Capital Management LLC acquired a new stake in shares of ADMA Biologics during the third quarter worth approximately $701,000. Thrivent Financial for Lutherans purchased a new position in ADMA Biologics during the third quarter valued at approximately $3,802,000. First Turn Management LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at $13,293,000. Finally, Aviance Capital Partners LLC acquired a new position in ADMA Biologics in the 3rd quarter worth about $229,000. 75.68% of the stock is owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.